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ABSTRACT
Objective: The objective of this systematic review is to determine whether or not temporal lobe
resection cures seizures in epileptics.
Study Design: Systematic review of three English language, peer-reviewed randomized
controlled trials, published between 2001 and 2012
Data Sources: Two randomized controlled trials comparing temporal lobe resection surgery to
antiepileptic drugs in the treatment of epileptic seizures, and one randomized controlled trial
comparing 3.5 cm temporal lobe resection to 2.5 cm temporal lobe resection in the treatment of
epileptic seizures. Studies were obtained by the author through the PubMed database.
Outcomes Measured: Primary outcome measured by the three studies was control of seizures,
and additional outcomes measured included quality of life and cognitive function.
Results: The three randomized controlled trials found that temporal lobe resection treatment
significantly decreased the frequency and severity of seizures in patients with temporal lobe
epilepsy that was refractory to pharmacotherapy. Two of the three studies showed that temporal
lobe resection resulted in significantly higher rates of freedom from seizures and significantly
higher quality of life as compared to treatment with antiepileptic drugs alone. All three studies
showed that surgery poses an increased risk of complications and adverse events, including
decline in cognitive function.
Conclusions: Data suggests that temporal lobe resection surgery is more effective than medical
therapy alone in decreasing the frequency and severity of seizures in patients with temporal lobe
epilepsy that is refractory to pharmacotherapy. Temporal lobe resection is not a definitive cure
for seizures in epileptics, but research presented in these three studies shows that surgery is
superior to pharmacotherapy alone in controlling seizures. Further research is needed to
determine long-term efficacy in seizure reduction post-surgically, as well further assessment of
cost and safety of temporal lobe resection.
Key Words: Epilepsy, temporal lobe resection
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INTRODUCTION
A seizure is a sudden alteration in behavior, thought, and/or consciousness caused by
neuronal dysfunction in the brain.1 Epileptic seizures specifically are due to electric
hypersynchronization of neurons in the cerebral cortex, and these seizures occur independently
of provocation by specific events.1 Epilepsy is characterized by recurrent epileptic seizures (2 or
more).1 Greater than one half of epileptic seizures have no identifiable underlying cause,1 which
makes the treatment of epilepsy difficult because there often is no underlying etiology to be
corrected. Although a cause of epilepsy may not be readily identifiable, seizures can often be
localized to the specific portion of the brain they are coming from based on interpretation of
electroencephalogram (EEG) studies. Of the cases of epilepsy that can be localized, temporal
lobe epilepsy is the most common form of the disorder.2
Epilepsy is a serious health problem that affects both men and women of all races, ages,
geographic regions, and socioeconomic backgrounds.3 The prevalence of epilepsy is five to ten
per 1000 in North America.3 There are currently 2.9 million individuals in the Unites States
diagnosed with epilepsy, accounting for 1% of adults and 0.6% of children.4 Many cases of
epilepsy are well controlled by pharmacotherapy, but there is still a large percentage of
individuals with this disease that do not achieve a seizure-free life. The total indirect and direct
cost of epilepsy in the Unites States annually is $15.5 billion.4 For those with medically
controlled epilepsy, the cost is $2,000 per year, whereas patients with medically uncontrolled pay
roughly $10,000 per year in medical bills.5 All epileptic patients average 10 physician visits per
year and greater than 30 drug dispensings per year.6 Epilepsy is the second most common cause
of mental health disability in the Unites States.3
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The typical approach to managing epilepsy includes pharmacotherapy targeted at
resolving or decreasing frequency of seizures. This is best done through the use of antiepileptic
drugs (AEDs). Some of the most commonly used antiepileptic agents include phenytoin,
lamotrigine, carbamazapine, gabapentin, topiramate, and valproate.1 For some patients, AEDs
greatly decrease the frequency of seizures, and sometimes even achieve lifelong freedom
seizures. As many as 20-40% of patients, however, will have seizures that are refractory to
AEDs.7 Seizures cause patients to have impaired psychosocial functioning and decreased quality
of life.4 Because there is still such a large percentage of patients with epilepsy whose seizures are
not controlled by medication, and because recurrent seizures can cause patients to have a poor
quality of life, there has been more and more research in developing other means of treatment for
epilepsy.
Of all cases of epilepsy that are refractory to pharmacotherapy, 50-73% are localized
temporal lobe epilepsy.2 Seizures in temporal lobe epilepsy range from simple partial seizures
characterized by auras and preserved awareness, to complex partial seizures with loss of
awareness and sometimes convulsions.3 Temporal lobe epilepsy is the form that is most
amenable to surgical treatment.5 Therefore, much of the new epilepsy research focuses on brain
surgery in patients with temporal lobe epilepsy, in attempt to find a treatment for seizures in
patients with medically uncontrolled epilepsy.

OBJECTIVE
The objective of this systematic review is to determine whether or not temporal lobe
resection cures seizures in epileptics.
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METHODS
Criteria used for the selection of studies for this review included randomized controlled
trials including persons greater than 12 years old with temporal lobe epilepsy whose seizures
were not controlled with AEDs. All studies included an intervention of partial temporal lobe
resection surgery with a comparison group of antiepileptic medication. Common outcomes that
were evaluated by the three studies were control of seizures, quality of life, and cognitive
function. Research was conducted by the author by collecting relevant articles through the
PubMed database, using the keywords “temporal lobe resection” and “epilepsy” to find
appropriate studies. All articles were published in English in peer-reviewed journals. Studies
were selected based on relevance to the clinical question and based on relevance to patients and
patient oriented outcomes (POEMs). Inclusion criteria included studies published after the year
2000 that were randomized controlled trails, including a population of patients with temporal
lobe epilepsy who have previously failed pharmacotherapy with AEDs. Exclusion criteria
included patients under 12 years old, patients with psychosis, substance use disorder, eating
disorder, IQ below 70, abnormalities on neuroimaging, and patients who have had previous brain
surgery for epilepsy. Statistics reported in these studies were p-values and 95% confidence
intervals, and the author calculated numbers needed to treat (NNT), relative risk reduction
(RRR), absolute risk reduction (ARR), numbers needed to harm (NNH), relative risk increase
(RRI), and absolute risk increase (ARI) using dichotomous data found in the studies.
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Table 1: Demographics & Characteristics of Included Studies
Study

Type

# Pts

Engle
(2012)

RCT

38

Wiebe
(2001)

RCT

80

! 16
yo

207

! 18
yo

Schramm RCT
(2011)

Age
(yrs)
! 12
yo

Inclusion
Criteria
Pts 12 yrs and
older with
mesial
temporal lobe
epilepsy that
have tried and
failed at least 2
AEDs
Pts 16 yrs and
older with
temporal lobe
epilepsy whose
seizures occur
at least
monthly and
were poorly
controlled with
AEDs, one of
which being
phenytoin,
carbamazepine,
or valproic
acid
Pts 18 yrs and
older with
mesial
temporal lobe
epilepsy that
have tried and
failed at least 2
AEDs at
maximum
tolerated doses,
seizure
duration > 2
yrs, must be
available for
follow up after
1 yr

Exclusion Criteria

W/D

Interventions

Pts with psychosis,
suicidal risk,
substance abuse,
eating disorders,
IQ < 70, nonepileptic seizures,
abnormalities on
brain MRI
Pts with psychosis,
pseudo-seizures,
IQ < 70, CNS
disorders,
abnormalities on
brain MRI, focal
temporal spikes or
slowing on EEG,
pts who have had
previous surgery
for epilepsy

1

Anteromesial
temporal
lobe
resection
surgery

1

6.0-6.5 cm
resection of
the anterior
lateral nondominant
temporal
lobe or 4.04.5 cm
resection of
the dominant
temporal
lobe

Pts with
0
abnormalities on
brain MRI,
neuropsychological
abnormalities, pts
who have had
previous temporal
lobe surgery,
seizure duration <
2 yrs

3.5 cm
temporal
lobe
resection
surgery vs.
2.5 cm
temporal
lobe
resection
surgery
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OUTCOMES MEASURED
All three studies measured control of seizures, quality of life, and cognitive function.
Control of seizures was measured with the ictal subscale of the Liverpool Seizure Severity Scale,
through patients’ seizure diaries, and through Engel class categories. Quality of life was
measured with Quality of Life in Epilepsy Inventory-89 for adults 17 years and older and Quality
of Life in Epilepsy-48 for adolescents 16 years and younger, and through records of hours
worked per week, number of sick days from school or work, and number of hospitalizations.
Cognitive function was measured using clinical neuropsychological measures of visual and
auditory attention, motor/speed dexterity, verbal and visuospatial memory, and word finding
ability.

RESULTS
The three randomized controlled trials included in this review compared partial temporal
lobe resection surgery to the control group of pharmacotherapy with AEDs. One study also
compared a 2.5 cm to a 3.5 cm temporal lobe resection.
In the randomized controlled trial by Engle et al8, 38 participants age 12 years and older
with mesial temporal lobe epilepsy and disabling seizures were randomized into a surgical group
and a medical group. The surgical treatment included anteromesial temporal lobe resection
performed by experienced neurosurgeons. The comparison group (medical treatment) included
use of antiepileptic medication. Prior to this study, all participants must have tried at least two
AEDs within the past two years, which failed to control seizures. The primary outcome measured
in this study was freedom from disabling seizures at year two of follow-up. Secondary outcomes
measured were health-related quality of life and cognitive function. At year two of follow-up,
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zero of 23 patients in the medical group were seizure-free, and 11 of 15 patients in the surgical
group were seizure free (95% CI, 11.8 to !; P < 0.001)8, as portrayed in Table 2. Numbers
needed to treat (NNT) was also calculated in Table 2, and it was found that for every two
patients with epilepsy that undergo temporal lobe resection surgery, one more person will remain
free from seizures as compared to the medical group. Additionally, quality of life was higher in
the surgical group than in the medical group, but the difference was not statistically significant
(95% CI -1.0 to 18.1; P = 0.08).8 Four participants in the surgical group experienced memory
decline, representing a decline in cognitive function,8 but the sample of participants in this study
was too small to make definitive conclusions about differences in cognitive outcomes between
the two groups.8 Additional adverse events included a post-operative stroke leading to transient
neurologic deficit in one patient in the surgical group, and three cases of status epilepticus in the
medical group.8 Based on this information, numbers needed to harm (NNH) was calculated in
Table 3. Based on the adverse events that occurred in this study, it was calculated that for every
four patients with epilepsy that undergo temporal lobe resection surgery, one more adverse event
will occur as compared to the medical group.
Wiebe et al3 conducted a similar study in which 80 participants were randomized into
either a surgical group (40 patients) or a medical group (40 patients). The surgical group
underwent a 4.0-4.5 cm resection of the temporal lobe if seizures originated from the dominant
temporal lobe (based on EEG findings) or a 6.0-6.5 resection of the temporal lobe if seizures
originated form the non-dominant temporal lobe. After surgery, patients were started on AEDs.
The medical comparison group underwent one year of AED therapy. After one year, experienced
epileptologists blindly evaluated patients for the primary outcomes, which was freedom from
seizures impairing awareness and freedom from all seizures, and for quality of life. Results
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showed that after one year, proportion of patients who were free from seizures impairing
awareness was 58% in the surgical group and 8% in the medical group (p < 0.001).3 Patients in
the surgical group also had a lower incidence of seizures altogether. After one year the
proportion of patients who had no seizures in the past year was 38% in the surgical group and
3% in the medical group (p < 0.001).3 Table 2 displays NNT for both freedom from seizures
impairing awareness and freedom from all seizures. It was found that for every two patients with
epilepsy that undergo temporal lobe resection surgery, one more person will remain free from
seizures that impair awareness as compared to the medical group, and for every three patients
with epilepsy that undergo temporal lobe resection surgery, one more person will remain free
from all seizures as compared to the medical group. Patients in the surgical group also had a
significantly better quality of life (p < 0.001).3
While the study conducted by Wiebe et al3 showed better seizure control in the surgical
group as compared to the medical group, there were higher rates of adverse effects in the surgical
group. Significant post-operative adverse events (difficulties with memory) developed in 5% of
the surgical group as compared to zero in the medical group.3 NNH was calculated in Table 3,
showing that for every 20 patients with epilepsy that undergo temporal lobe resection surgery,
one more adverse event will occur as compared to the medical group.
The randomized controlled trial conducted by Schramm et al9 was slightly different that
the other two randomized controlled trials in this review. This study compared two surgical
groups rather than a surgical group to a medical group. Two hundred and seven patients were
randomized into a surgical group that underwent a 2.5 cm resection of the affected temporal lobe
(104 patients) and a surgical group that underwent a 3.5 cm resection of the affected temporal
lobe (103 patients). After one year, seizure freedom analysis showed that 74% of patients in the
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2.5 cm resection group and 73% of patients in the 3.5 cm resection group were free from
seizures. There was no statistical significance between the two groups (p = 0.843).9 Table 2
further exemplifies the lack of significant difference between these two surgical groups.

Table 2. Percentage of patients free from seizures after one year, relative and absolute risk
reduction, and numbers needed to treat
% Seizure Free
(Medical Group)

% Seizure Free
(Surgical Group)

p

RRR

ARR NNT

Engle*
0
73%
< 0.001
-73%
2
(2012)
Wiebe
8%
58%
< 0.001 6.25 50%
2
(2001)**
Wiebe
3%
38%
< 0.001 11.7 35%
3
(2001)***
Schramm
73%
74%
0.843
0.014 1%
100
(2011)****
* Engle et al8 assessed freedom from seizures after two years (no assessment at one year)
** Freedom from seizures impairing awareness
*** Freedom from all seizures
**** No medical group in Schramm study; 73% seizure free in medical group column represents
3.5 cm resection group and 74% seizure free in surgical group column represents 2.5 cm
resection group

Table 3. Percentage of patients who experienced adverse effects of treatment, relative and
absolute risk increase. and numbers needed to harm
% Harmed (Medical Group) % Harmed (Surgical Group) RRI ARI NNH
Engle (2012)
9%
33%
2.7 24%
4
Wiebe (2001)
0
5%
-5%
20
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DISCUSSION
All three studies included in this review propose temporal lobe resection surgery as a
treatment for patients with temporal lobe epilepsy that has been refractory to treatment with
AEDs. Two of these studies (Engle et al8 and Wiebe et al2) compared temporal lobe resection
surgery to conventional medical treatments of pharmacotherapy with AEDs. Both of these
studies showed significantly higher rates of seizure control in the surgical group compared to the
medical group (p < 0.001). Both studies showed that after one year, surgical groups not only
achieved higher rates of seizure freedom, but also had higher rates of quality of life. Contrarily,
both of these studies showed that there were greater adverse events including decline in cognitive
function in the surgical group compared to the medical group.
Based on the results of the randomized controlled trials by Engle et al8 and Wiebe et al2,
there is strong supporting evidence that temporal lobe resection is more effective in reducing
seizures than AED therapy alone. It is important to note that the sample size of patients in each
of these studies is relatively small, and a much larger population will need to be studied in order
to make any definitive conclusions. It is difficult to study large populations when it comes to
performing invasive procedures like resection of a portion of the temporal lobe of the brain. Not
only does this surgery pose risks of adverse effects such as lifelong cognitive impairment, but it
is also extremely expensive. Patients with epilepsy need to be extensively evaluated before being
deemed candidates for surgery, which means enduring numerous costly tests. However, the idea
is that patients would have significantly lower rates of seizures post-surgically, and therefore
would not have to continue paying the annual medical bills of $10,000 for uncontrolled
epilepsy.5 With risks of adverse events, high costs of the testing and procedure, and strict criteria
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for eligible patients, it is difficult to include large populations in studies of temporal lobe
resection in treatment of seizures in patients with pharmacoresistant temporal lobe epilepsy.
In the study conducted by Schramm et al9, there was no statistical difference between
patients who underwent a 2.5 cm temporal lobe resection compared to patients who underwent a
3.5 cm temporal lobe resection. There was, however, a large percentage of patients in each group
(74% in the 2.5 cm group and 73% in the 3.5 cm group) who remained seizure-free after one
year of surgery, indicating that temporal lobe resection, regardless of the size of resection, is
effective in preventing seizures in patients with temporal lobe epilepsy. Schramm et al9
concluded that it is adequate resection size rather than larger resection size that helps achieve
seizure freedom in patients.
One of the major limitations of all three of these studies is the short time for follow-up.
Patients were assessed for seizure activity at one year in the studies by Wiebe et al3 and
Schramm et al,9 and at two years in the study by Engle et al.9 When analyzing whether temporal
lobe resection is a cure for epileptic seizures, the follow-up would need to be for a much longer
period of time. Given this short time of follow-up, we are not able to assess long-term efficacy,
long-term adverse effects, or and changes in the status of patients.

CONCLUSION
The three randomized controlled trials included in this review provide statistically
significant evidence that temporal lobe resection is effective in the treatment of seizures in
patients with temporal lobe epilepsy that is refractory to treatment with AEDs. While evidence
shows that temporal lobe resection greatly decreases the frequency and severity of seizures in
patients with temporal lobe epilepsy, surgery is not a definitive cure for seizures in epilepsy.
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More extensive research needs to be conducted in order to follow surgical patients for longer
periods of time in order to further assess the efficacy of temporal lobe resection in reducing
seizures.
It is important to note that temporal lobe resection often comes with complications.
Further research needs to be done in order to evaluate the safety of temporal lobe resection
surgery. Patients will often need to weigh the risks vs. benefits of undergoing such an intensive
procedure. Additionally, not all patients with this condition are candidates for invasive brain
surgery. Ongoing research is still warranted concerning the safety, cost, patient qualifications,
and efficacy of temporal lobe resection surgery compared to AEDs, but based on the information
in these three randomized controlled trials in this review, we can say that temporal lobe resection
offers better control of seizures in patients with temporal lobe epilepsy compared to AEDs alone.
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